- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03588884
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
November 14, 2022 updated by: OPKO Health, Inc.
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Garden Grove, California, United States, 92844
- National Institute of Clinical Research, Inc.
-
-
Illinois
-
Chicago, Illinois, United States, 60643
- Research by Design, LLC
-
-
Wisconsin
-
West Bend, Wisconsin, United States, 53095
- Spaulding Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be at least 18 years of age.
- Have stage 3 or 4 CKD (estimated glomerular filtration rate [eGFR] of ≥15 to <60 millilter per minute per 1.73 meter square (mL/min/1.73 m2) using the Modification of Diet in Renal Disease equation).
Be without any disease state or physical condition that might impair evaluation of safety and efficacy or which, in the Investigator's opinion, would interfere with study participation, including:
- Serum albumin ≤ 3.0 (grams per deciliter (g/dL);
- Serum transaminase (alanine transaminase, glutamic pyruvic transaminase, aspartate aminotransferase or glutamic oxaloacetic transaminase) > 2.5 times the upper limit of normal at screening; and,
- Urinary albumin excretion ≤3000 microgram per milligram (μg/mg) creatinine.
Exhibit during the initial screening visit:
- Plasma intact parathyroid hormone (iPTH) ≥70 picogram per milliliter (pg/mL) and <400 pg/mL if receiving calcitriol or other 1α- hydroxylated vitamin D analog (paricalcitol or doxercalciferol); or
- Plasma iPTH ≥100 pg/mL and <500 pg/mL if not receiving calcitriol or other 1α- hydroxylated vitamin D analog; and,
- Serum total 25-hydroxyvitamin D <30 nanogram per milliliter (ng/mL).
- If taking calcitriol, other 1α-hydroxylated vitamin D analog, or vitamin D supplementation, must forgo treatment with these non-study agents for the duration of the study and undergo a 4-week washout period.
Exhibit after the 4-week washout period (if required):
- Plasma iPTH ≥100 pg/mL and <500 pg/mL;
- Corrected serum calcium <9.8 mg/dL; (corrected for serum albumin)
- Serum total 25-hydroxyvitamin D <30 nanogram per milliliter (ng/mL); and,
- Serum phosphorus <5.5 milligram per deciliter (mg/dL).
- If taking more than 1,500 milligram per day (mg/day) of elemental calcium, reduce calcium use (to approximately 1,000 to ≤1,500 mg/day) for the duration of the study.
- Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study.
- Female subjects of childbearing potential must be neither pregnant nor lactating and must have negative blood pregnancy tests at the first screening visit.
- All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
- Be able to read, understand and sign the subject Informed Consent Form (ICF) or have a legal authorized representative (LAR) sign the ICF.
Exclusion Criteria:
- History of or planned kidney transplant or parathyroidectomy
- History (prior 3 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus ≥5.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.
- Need for phosphate binders to maintain the serum phosphate < 5.5 mg/dL or use of phosphate binders within 4 weeks prior to screening
- Use of calcimimetic therapy (cinacalcet or etelcalcetide) within 12 weeks of screening.
- Receipt of bisphosphonate therapy or other bone modifying treatment within 6 months prior to enrollment.
- Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease, intestinal malabsorption disorder, hepatitis or cardiovascular event that in the opinion of the Investigator may worsen or reduce life expectancy, and/or interfere with participation in the study.
- History of neurological/psychiatric disorder, including psychotic disorder or dementia, or any reason which, in the opinion of the Investigator makes adherence to a treatment or follow-up schedule unlikely.
- Known or suspected hypersensitivity to any of the constituents of the study drugs.
- Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CTAP101
CTAP101/Calcifediol Capsules 60 micrograms (mcg) once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
|
Capsule, daily
Other Names:
|
Experimental: Immediate-release (IR) calcifediol
Immediate-release (IR) calcifediol/266 micrograms (mcg) capsule before breakfast on the mornings of Day 1 and Day 29
|
Capsule, once a month
|
Experimental: Cholecalciferol
Cholecalciferol/Capsules 300,000 International Units (IU) (high-dose) before breakfast on the mornings of Day 1 and Day 29
|
Capsule, once a month
|
Active Comparator: Paricalcitol
Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and29 when dosing will occur before breakfast
|
Capsule, once a month
Capsule, daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and Severity of Treatment-Emergent Adverse Events (TEAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time Frame: 5 months
|
This study is descriptive and no primary or secondary efficacy endpoints are defined.
|
5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2018
Primary Completion (Actual)
April 24, 2020
Study Completion (Actual)
April 24, 2020
Study Registration Dates
First Submitted
June 28, 2018
First Submitted That Met QC Criteria
July 16, 2018
First Posted (Actual)
July 17, 2018
Study Record Updates
Last Update Posted (Estimate)
December 9, 2022
Last Update Submitted That Met QC Criteria
November 14, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urologic Diseases
- Endocrine System Diseases
- Renal Insufficiency
- Parathyroid Diseases
- Neoplastic Processes
- Kidney Diseases
- Renal Insufficiency, Chronic
- Hyperparathyroidism
- Neoplasm Metastasis
- Hyperparathyroidism, Secondary
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
- Calcifediol
Other Study ID Numbers
- CTAP101-CL-4001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Insufficiency
-
Boston UniversityPure North S'Energy FoundationCompletedVitamin D InsufficiencyUnited States
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)CompletedPhysical Function | Vitamin D InsufficiencyUnited States
-
University of Wisconsin, MadisonCompletedVitamin D Deficiency | Vitamin D InsufficiencyUnited States
-
Boston UniversityCompletedVitamin D Deficiency | Vitamin D InsufficiencyUnited States
-
Johns Hopkins UniversityBariatric AdvantageTerminatedVitamin D Deficiency | Vitamin D InsufficiencyUnited States
-
Boston UniversityCompletedVitamin D Deficiency | Vitamin D InsufficiencyUnited States
-
University College CorkIrish Government Department of Agriculture, Food and Fisheries, IrelandCompletedVitamin D Deficiency | Vitamin D InsufficiencyIreland
-
University of Colorado, DenverNational Center for Research Resources (NCRR)CompletedVitamin D Deficiency | Vitamin D InsufficiencyUnited States
-
Dong-A UniversityCompletedVitamin D Deficiency | Vitamin D Insufficiency | Hemodialysis PatientsKorea, Republic of
-
Sahlgrenska University Hospital, SwedenCompletedVitamin-D InsufficiencySweden
Clinical Trials on Calcifediol Oral Capsule
-
OPKO Health, Inc.Active, not recruitingChronic Kidney Diseases | Vitamin D Deficiency | Stage 5 Chronic Kidney Disease | Secondary Hyperparathyroidism Due to Renal CausesUnited States
-
Parc de Salut MarHospital Clinic of Barcelona; Universidad Complutense de Madrid; Hospital Universitario... and other collaboratorsNot yet recruitingPulmonary Artery Hypertension | Vitamin d Deficiency
-
University Hospital of North NorwayUniversity of Tromso; Cornell University; The Royal Norwegian Ministry of HealthCompletedPsoriasis | Vitamin D DeficiencyNorway
-
Brigham and Women's HospitalCompleted
-
Aelis FarmaNational Institute on Drug Abuse (NIDA)CompletedHealthy VolunteersUnited States
-
Brigham and Women's HospitalEnrolling by invitation
-
EicOsis Human Health Inc.National Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy AdultsUnited States
-
Brigham and Women's HospitalCompleted
-
Yale UniversityNeurocrine BiosciencesRecruitingTrichotillomania (Hair-Pulling Disorder)United States
-
Alkermes, Inc.Terminated